医药生物：从阿托品看近视防控市场

Investment Rating - The report indicates a positive outlook for the ophthalmic drug market in China, with specific emphasis on myopia control and dry eye treatment as key growth areas [2][4]. Core Insights - The ophthalmic drug market in China is expected to grow at a faster rate than the global market, with a projected increase from approximately $2.6 billion in 2019 to $20.2 billion by 2030 [2][4]. - Myopia treatment, particularly with low-concentration atropine, is anticipated to become a significant market segment, with a conservative market size estimate of approximately 5.29 billion yuan and an optimistic estimate of 20.39 billion yuan by 2026 [2][17]. - The prevalence of dry eye disease is also on the rise, with the number of patients expected to grow from 210 million in 2019 to 270 million by 2030, indicating a sustained demand for treatment options [25][27]. Summary by Sections Myopia Control Market - The myopia prevalence among children and adolescents in China is alarmingly high, with a current rate of 52.7%, leading to a significant demand for effective control measures [11][14]. - The report highlights that low-concentration atropine has been validated as an effective treatment for slowing myopia progression, with studies showing a reduction in eye axis growth by 19% to 29% [15][16]. - The anticipated market for atropine is substantial, with estimates suggesting that by 2026, around 1.3 billion yuan could be generated from its sales, given the high prevalence of myopia among the youth [17][18]. Dry Eye Treatment Market - The dry eye treatment market is projected to grow significantly, with the market size expected to increase from $430 million in 2019 to $6.7 billion by 2030 [27]. - Artificial tears and cyclosporine are identified as the primary treatment options for dry eye disease, with the market for artificial tears alone expected to reach $1.45 billion by 2030 [27]. - The report notes that the treatment for dry eye disease is characterized by a high rate of recurrence, which supports ongoing demand for these products [25][26]. Regulatory Environment - The regulatory landscape for atropine is stringent, with a history of being sold primarily as a hospital preparation. Recent approvals for commercial sales are expected to enhance market access [19][21]. - The report emphasizes the importance of adhering to medical guidelines when using atropine, particularly in pediatric populations, to mitigate potential risks associated with its use [19][21].